Fig. 1

FBX has a protective effect on body wall muscle cells. A–C Wild-type animals were cultured on a medium containing FBX at the concentration indicated on abscissae, and the numbers of body wall muscle cell nuclei in one bundle per animal were counted on Days 14 (A), 16 (B), and 18 (C). **P < 0.005. A Number of trials: three times for each condition. Total number of FBX (0, 5, 10, and 20 µg/ml)-treated animals: 43, 48, 45, and 44, respectively. Mean value of FBX (0, 5, 10, and 20 µg/ml)-treated animals: 18.37 (SEM, ± 0.37), 19.00 (SEM, ± 0.33), 19.49 (SEM, ± 0.25), and 19.14 (SEM, ± 0.43), respectively. B Number of trials: three times for each condition. Total number of FBX (0, 5, 10, and 20 µg/ml)-treated animals: 55, 52, 52, and 50, respectively. Mean value of FBX (0, 5, 10, and 20 µg/ml)-treated animals: 17.05 (SEM, ± 0.36), 18.65 (SEM, ± 0.28), 18.88 (SEM, ± 0.33), and 18.82 (SEM, ± 0.34), respectively. C Number of trials: three times for each condition. Total number of FBX (0, 5, 10, and 20 µg/ml)-treated animals: 54, 54, 52, and 42, respectively. NS, not significant. Mean value of FBX (0, 5, 10, and 20 µg/ml)-treated animals: 16.02 (SEM, ± 0.47), 17.24 (SEM, ± 0.42), 17.79 (SEM, ± 0.31), and 16.60 (SEM, ± 0.42), respectively. D Representative images of the body wall muscle nuclei at Day 16. Two bundles of nuclei are seen in the focal plane. The number of visible nuclei is decreased in the area encircled by the dotted line at the FBX-free condition. Arrowheads indicate nuclei visible in FBX-treated animals but not visible in FBX-free condition